Overview

A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
To investigate the clinical benefits of Docetaxel or alternating AC-Docetaxel in comparison with standard AC for metastatic breast cancer
Phase:
Phase 3
Details
Lead Sponsor:
Japan Clinical Oncology Group
Collaborator:
Ministry of Health, Labour and Welfare, Japan
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin